Glucagon-like peptide-1 (GLP-1) receptor agonists marked a key advancement in T2DM treatment by enhancing insulin secretion, inhibiting glucagon release, slowing gastric emptying, and reducing appetite, thus supporting both glycemic control and weight loss [4, 5]. This evidence concerns the gene GCG and type 2 diabetes mellitus.